US biotech Eikon Therapeutics (Nasdaq: EIKN) has raised about $381 million in the largest biotech IPO of the year so far, but ...

Pfizer today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the ...

Swiss biotech firm Idorsia today announced the design of its US Food and Drug Administration (FDA)-agreed Phase III ...

M&A activity in the pharmaceutical and biotechnology sectors in January was active but skewed toward mid-size strategic ...

In the UK, local authorities have agreed a partnership with specialist developer Prologis (NYSE: PLD) to support the next ...

Having been pushed back from an expected January launch, the US government's TrumpRx website - intended to offer discounts on ...

Following on from a host of successful or planned initial public offerings (IPOs) in biotech so far this year, another firm ...

German drugmaker Bayer (BAYN: DE) has revealed positive late-stage results for its investigational once-daily oral ...

Danish drugmaker's Novo Nordisk’s shares fell more than 8% on Thursday after Hims & Hers announced that it would be releasing ...

Swedish life sciences investor Karolinska Development (Nasdaq Stockholm: KDEV) says its portfolio company SVF Vaccines has ...

Privately-held San Diego biotech ADARx Pharmaceuticals announced the appointment of Dr Donald Fong as chief medical officer ...

Chinese biotech Kelun-Biotech (HKEX: 6990) has won a new approval from China’s National Medical Products Administration for sac-TMT (sacituzumab tirumotecan), a TROP2-directed antibody-drug conjugate.